BioNTech SE BNTX

BioNTech (NasdaqGS:BNTX) reported that its Phase 2/3 trial of BNT113 in head and neck cancer did not meet the progression-free survival primary endpoint. The company is keeping the trial active to continue evaluating overall survival as a key secondary outcome measure. BNT113 is part of BioNTech's mRNA-based oncology portfolio that targets HPV16-positive head and neck tumors. To put this update on BioNTech in context, consider reviewing other healthcare and AI-focused stocks via 33...

Investing.com --BioNTech (NASDAQ: BNTX) shares fell 5% on Tuesday after the company announced that a mid-to-late-stage clinical trial for its experimental mRNA cancer drug, BNT113, missed its first major goal.

AHEAD-MERIT Phase 2/3 clinical trial did not meet its first dual primary endpoint of progression-free survival for the mRNA cancer immunotherapy candidate BNT113 plus pembrolizumab compared with pembrolizumab alone The trial will continue to evaluate the second dual primary endpoint of overall survival completing the assessment with the potential of this treatment approach to help patients live longerUnder the trial’s pre-specified statistical design, a statistically significant improvement in o

BioNTech (NasdaqGS:BNTX) last closed at US$96.96, leaving investors weighing how current pricing aligns with recent trading returns and the company’s evolving mix of oncology candidates and infectious disease programs. Recent trading has been choppy for BioNTech. The share price return over the past 90 days of 5.98% hints at some rebuilding momentum, yet the 1 year total shareholder return declined 5% and the 5 year total shareholder return fell 60.47%. This shows that longer term holders are...

Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds finish their mechanical purchases and attention shifts back to the pipeline.

BioNTech has seen its share price slide over recent years while the business reshapes itself beyond the COVID-19 vaccine boom, which naturally puts the focus back on what investors are paying for its current and potential sales base. With market sentiment shifting around the restructuring of its manufacturing footprint and the oncology pipeline, the live question is how well the present US$95.73 price lines up with the revenue the company is generating and expects to generate. The stock has...

Moderna stock has turned a handful of patient shareholders into believers, but a gain this size forces a choice that most investors never plan for in advance. The pipeline promise is real, and so is the risk of giving it all back.

Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has actually seen in full. What happens when Madrid finally puts the complete data in front of the market?

Citigroup just told investors to sell Moderna and the stock responded by climbing 3%, raising one pointed question about whether pipeline optimism has fully broken free from Wall Street's valuation warnings.

In mid-September 2026, Pfizer Canada and BioNTech announced Health Canada’s approval of the Omicron XFG‑adapted COMIRNATY vaccine for individuals aged 6 months and older, aligning with 2026–2027 public health recommendations. A few days earlier, BioNTech and OncoC4 reported that investigational CTLA‑4 antibody gotistobart nearly doubled median overall survival versus chemotherapy in a Phase 3 lung cancer trial stage, underscoring BioNTech’s expanding presence in late‑stage oncology. We’ll...